172 results
Page 5 of 9
8-K
EX-99.1
ve7o2f6o rk58zy4c4x4
29 Apr 20
Other Events
8:06am
8-K
bzui9e
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
688um2hzxv0i4uwc
28 Apr 20
Other Events
8:26am
8-K
EX-99.1
3gjiss54mr9m5o 8ih66
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
8-K
EX-99.1
ozxsmk rqeowm
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
ats lm8xagxzpg
7 Feb 20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
4:20pm
424B5
48sna4v2ua7yvigk4 jn
22 Jan 20
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.2
9xrj7efc7441v
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.1
t6fun
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-1.1
koly3xmb0z3 3w0hphl
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
424B5
b9o0gj y7eemwf
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
2qntx272x0
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
yj9aao
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
xo6q9lpxsh99ol1
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am